Compare Quest Diagnostics Inc (DGX) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs 8x8 Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while 8x8 Inc trades at $2.17 (market cap $309.09M). The key difference: Quest Diagnostics Inc is far larger — about 73.8× 8x8 Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| DGX | EGHT | |
|---|---|---|
Market Cap | $22.80B | $309.09M |
Sector | Health | Technology |
52-Week High | $216.02 | $2.76 |
52-Week Low | $166.42 | $1.59 |
Enterprise Value | $28.82B | $586.76M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EGHT trades at $2.22, up 8.29% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent product innovations in AI routing and workforce management demonstrate growth potential, though high P/E ratio of 218 and negative net income require careful valuation assessment.
EGHT presents a turnaround story with improving earnings momentum and AI-driven product expansion, but faces significant execution risks amid high valuation multiples. The stock's technical strength contrasts with fundamental challenges, requiring balanced risk-reward evaluation for investors seeking growth opportunities in communications technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
